其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

N-Hydroxyphthalimide CAS Registry Number: 524-38-9 N-羟基邻苯二甲酰亚胺

CAS Name: 2-Hydroxy-1H-isoindole-1,3(2H)-dione
Additional Names: NHPI
Percent Composition: C 58.90%, H 3.09%, N 8.59%, O 29.42%
Literature References: Mediates oxidative catalytic transformations of organic compounds with molecular oxygen. Prepn: L. Cohn, Ann. 205, 295 (1880); H. Gross, I. Keitel, J. Prakt. Chem. 311, 692 (1969). Crystal structure: F.-M. Miao et al., Acta Crystallogr. C51, 712 (1995). Transition metal free oxidation reactions: C. Einhorn et al., Chem. Commun. 1997, 447; epoxidation of alkenes: T. Iwahama et al., Heterocycles 52, 693 (2000). Transition metal cocatalysis in alkane oxidation: Y. Ishii et al., J. Org. Chem. 61, 4520 (1996); in hydroxylation of fatty acids: M. A. Oakley et al., J. Mol. Catal. A 150, 105 (1999). Description of catalytic mechanisms: Y. Ishii, S. Sakaguchi, Catal. Surv. Jpn. 3, 27 (1999).

Fenoxanil CAS Registry Number: 115852-48-7 稻瘟酰胺

CAS Name: N-(1-Cyano-1,2-dimethylpropyl)-2-(2,4-dichlorophenoxy)propanamideTrademarks: Achieve (BASF)
Percent Composition: C 54.72%, H 5.51%, Cl 21.54%, N 8.51%, O 9.72%
Literature References: Melanin biosynthesis inhibitor for control of rice blast fungus. Commercial product consists of a mixture of 4 isomers: 85% (R,RS) and 15% (S,RS). Prepn (stereochem unspec): W. Buck, E. Raddatz, EP 262393 (1987 to Shell). Review of properties and field trials: E. Sieverding et al., Brighton Crop Prot. Conf. - Pests Dis. 1998, 359-366.

Ramelteon CAS Registry Number: 196597-26-9 雷美替胺

CAS Name: N-[2-[(8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propanamideTrademarks: Rozerem (Takeda)
Percent Composition: C 74.10%, H 8.16%, N 5.40%, O 12.34%
Literature References: Melatonin MT1/MT2 receptor agonist. Prepn: S. Ohkawa et al., WO 9732871; eidem US 6034239 (1997, 2000 both to Takeda); O. Uchikawa et al., J. Med. Chem. 45, 4222 (2002). Pharmacology: N. Yukuhiro et al., Brain Res. 1027, 59 (2004). Receptor binding study: K. Kato et al., Neuropharmacology 48, 301 (2005). Reviews of development and therapeutic potential: C. Cajochen, Curr. Opin. Invest. Drugs 6, 114-121 (2005); N. N. Nguyen et al., Formulary 40, 146-155 (2005).

Agomelatine CAS Registry Number: 138112-76-2 阿戈美拉汀

CAS Name: N-[2-(7-Methoxy-1-naphthalenyl)ethyl]acetamideTrademarks: Valdoxan (Biopharma)
Percent Composition: C 74.05%, H 7.04%, N 5.76%, O 13.15%
Literature References: Melatoninergic agonist and selective serotonin 5-HT2B and 5-HT2C receptor antagonist; metabolically stable analogue of melatonin, q.v. Prepn: J. Andrieux et al., EP 447285; eidem, US 5225442 (1991, 1993 both to Adir); and structure-activity studies: S. Yous et al., J. Med. Chem. 35, 1484 (1992); P. Depreux et al., ibid. 37, 3231 (1994). Mechanism of action: M. J. Millan et al., J. Pharmacol. Exp. Ther. 306, 954 (2003). Clinical evaluation in major depressive disorder: H. Lôo et al., Int. Clin. Psychopharmacol. 17, 239 (2002); S. H. Kennedy, R. Emsley, Eur. Neuropsychopharmacol. 16, 93 (2006).

TNAZ CAS Registry Number: 97645-24-4

CAS Name: 1,3,3-Trinitroazetidine
Percent Composition: C 18.76%, H 2.10%, N 29.17%, O 49.97%
Literature References: Melt-castable nitramine explosive. Synthesis and crystal structure: T. G. Archibald et al., J. Org. Chem. 55, 2920 (1990). Alternate synthesis: A. R. Katritzky et al., J. Heterocycl. Chem. 31, 271 (1994); T. Axenrod et al., J. Org. Chem. 60, 1959 (1995). Decomposition studies: P. Politzer, J. M. Seminario, Chem. Phys. Lett. 207, 27 (1993). Thermolysis: J. C. Oxley et al., J. Phys. Chem. 98, 7004 (1994). Review: S. Borman, Chem. Eng. News 72, 18-22 (Jan. 17, 1994).

Diazolidinyl Urea CAS Registry Number: 78491-02-8 重氮烷基脲

CAS Name: N-[1,3-Bis(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]-N,N'-bis(hydroxymethyl)urea
Additional Names: N-(hydroxymethyl)-N-(1,3-dihydroxymethyl-2,5-dioxo-4-imidazolidinyl)-N'-(hydroxymet...
Literature References: Member of a family of heterocyclic substituted urea compounds with formaldehyde releasing activity. Prepn: P. A. Berke, W. E. Rosen, WO 8100566; eidem, US 4271176 (both 1981 to Sutton). Chemistry, toxicity and antimicrobial activity: eidem, Cosmet. Toiletries 97, 49 (1982). Determn in cosmetic products: R. J. Geise et al., J. Soc. Cosmet. Chem. 45, 173 (1994). Review of use and safety assessment: J. Am. Coll. Toxicol. 9, 229-245 (1990).

Tirilazad CAS Registry Number: 110101-66-1 替拉扎特

CAS Name: (16a)-21-[4-(2,6-Di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methylpregna-1,4,-9(11)-triene-3,20-dione
Percent Composition: C 73.04%, H 8.39%, N 13.45%, O 5.12%
Literature References: Member of a novel class of nonglucocorticoid, 21-aminosteroid antioxidants known as lazaroids which inhibit lipid peroxidation and have cytoprotectant activity. Prepn: J. M. McCall et al., WO 8701706; eidem, US 5175281 (1987, 1992 both to Upjohn). Inhibition of iron-dependent lipid peroxidation in vitro: J. M. Braughler et al., J. Biol. Chem. 262, 10438 (1987). HPLC determn in plasma: J. W. Cox, R. H. Pullen, J. Chromatogr. 424, 293 (1988). Clinical pharmacokinetics: J. C. Fleishaker et al., J. Clin. Pharmacol. 33, 175, 182 (1993). Veterinary evaluation in endotoxemia of neonatal calves: M. L. Rose, S. D. Semrad, Am. J. Vet. Res. 53, 2305 (1992). Review: E. D. Hall, Ann. Neurol. 32, S137-S142 (1992). Review of efficacy and mechanism of action in experimental models of subarachnoid hemorrhage: idem, Eur. J. Anaesthesiol. 13, 279-289 (1996); of clinical trials in acute ischemic stroke: Tirilazad International Steering Committee, Stroke 32, 2257-2265 (2000).

Lazabemide CAS Registry Number: 103878-84-8 拉扎贝胺

CAS Name: N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide
Additional Names: N-(2-aminoethyl)-5-chloropicolinamide
Percent Composition: C 48.13%, H 5.05%, Cl 17.76%, N 21.05%, O 8.01%
Literature References: Member of a novel class of potent, reversible, and extremely selective monoamine oxidase type B (MAO-B) inhibitors. Prepn: R. Imhof, E. Kyburz, GB 2163746; eidem, US 4764522 (1986, 1988 both to Hoffmann-LaRoche). HPLC determn in plasma: R. Wyss, W. Philipp, J. Chromatogr. 507, 187 (1990). Neurochemical profile: W. E. Haefely et al., Adv. Neurol. 53, 505 (1990). Enzyme binding studies: J. Saura et al., J. Neurosci. 12, 1977 (1992). Clinical trial: Parkinson Study Group, Ann. Neurol. 33, 350 (1993).

Indinavir CAS Registry Number: 150378-17-9 茚地那韦

CAS Name: 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide<...
Literature References: Member of the novel hydroxyaminopentane amide class of HIV-1 protease inhibitors. Prepn: J. P. Vacca et al., EP 541168; eidem, US 5413999 (1993, 1995 both to Merck Co.); B. D. Dorsey et al., J. Med. Chem. 37, 3443 (1994). Diastereoselective synthesis: D. Askin et al., Tetrahedron Lett. 35, 673 (1994); P. E. Maligres et al., ibid. 36, 2195 (1995). Crystal structure of HIV-II protease complex: Z. Chen et al., J. Biol. Chem. 269, 26344 (1994). Antiviral activity and pharmacokinetics: J. P. Vacca et al., Proc. Natl. Acad. Sci. USA 91, 4096 (1994). HPLC determn in plasma and urine: E. Woolf et al., J. Chromatogr. A 692, 45 (1995). Metabolism in humans: S. K. Balani et al., Drug Metab. Dispos. 23, 266 (1995).

Actiphenol CAS Registry Number: 526-02-3 4-[2-(2-羟基-3,5-二甲基苯基)-2-氧代乙基]哌啶-2,6-二酮

CAS Name: 4-[2-(2-Hydroxy-3,5-dimethylphenyl)-2-oxoethyl]-2,6-piperidinedione
Additional Names: 3-(2-hydroxy-3,5-dimethylphenacyl)glutarimide; b-(3,5-dimethyl-2-hydroxybenzoylmethyl)glutarimide...
Literature References: Metabolic product found in culture filtrates of cycloheximide-producing actinomycetes (Streptomyces albulus): Highet, Prelog, Helv. Chim. Acta 42, 1523 (1959); Rao, J. Org. Chem. 25, 661 (1960). Synthesis: Johnson, ibid. 27, 3658 (1962). May be prepd from cycloheximide: Highet, Prelog, loc. cit. Structure-activity studies: Ennis, Biochem. Pharmacol. 17, 1197 (1968).